Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 6

Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC

,

Panelists discuss how, if the MARIPOSA trial shows an overall survival advantage exceeding 1 year, the amivantamab-lazertinib combination may see increased frontline use. Subsequent therapy options could include chemotherapy, targeted therapies based on resistance mechanisms, or clinical trials for emerging treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC
    EP. 2: EGFR-Mutated NSCLC Disease Risk Stratification
    EP. 3: Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC
    EP. 4: Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
    EP. 5: Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC
    Now Viewing
    EP. 6: Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC

    Video content above is prompted by the following:

    If the MARIPOSA overall survival data exceeds a 1-year advantage as is projected, do you anticipate seeing the amivantamab with lazertinib combination used more frequently in the frontline setting? If so, what treatment options are available for subsequent therapy?

    x